title: UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer.
abstract: Ubiquitin-like with PHD and ring finger domains 1 (UHRF1) is a novel anti-apoptotic gene, and overexpression of UHRF1 is involved in tumorigenicity. Here, immunohistochemistry was used to detect UHRF1 expression in non-muscle-invasive bladder cancer (NMIBC), and these data were examined for correlation with clinicopathological parameters and prognosis. The UHRF1 expression rate was 49.2% in a total of 118 bladder cancer tissues, which was significantly higher than in normal tissues, and UHRF1 expression has a significantly positive correlation with tumor grade (P = 0.027) and recurrence (P = 0.013). Survival analysis showed that UHRF1 high expression patients' mean survival time (42.59 months) was significantly shorter than that (71.36 months) of UHRF1 low expression patients (P = 0.0002). Multivariate analysis showed that UHRF1 overexpression was an independent prognostic factor for tumor recurrence (P < 0.0001). So UHRF1 may be a molecular marker to predict the recurrence of NMIBC.
authors: Department of Urology, Renji Hospital, School of Medicine Shanghai, Jiaotong University, No. 145 Shan Dong Middle Road, Shanghai 200001, China.
authors: Guo-Liang
authors: GL
authors: Yang
authors: Lian-Hua
authors: LH
authors: Zhang
authors: Juan-Jie
authors: JJ
authors: Bo
authors: Hai-Ge
authors: HG
authors: Chen
authors: Ming
authors: M
authors: Cao
authors: Dong-Ming
authors: DM
authors: Liu
authors: Yi-Ran
authors: YR
authors: Huang
references: J Cell Biol. 2002 Jun 10;157(6):909-14
references: 12058012
references: J Urol. 2000 Jan;163(1):73-8
references: 10604317
references: Hum Pathol. 2005 Oct;36(10):1101-7
references: 16226110
references: Oncogene. 2008 Apr 3;27(15):2187-97
references: 17934516
references: Clin Cancer Res. 2005 Jul 1;11(13):4724-32
references: 16000567
references: Br J Cancer. 2009 Jul 7;101(1):98-105
references: 19491893
references: BJU Int. 2005 Feb;95(3):425-31
references: 15679808
references: Mamm Genome. 1998 Dec;9(12):1032-5
references: 9880673
references: Mol Biol Cell. 2005 Dec;16(12):5621-9
references: 16195352
references: Cancer Res. 2000 Jan 1;60(1):121-8
references: 10646863
references: Nature. 2008 Oct 9;455(7214):818-21
references: 18772891
references: Oncogene. 2004 Oct 7;23(46):7601-10
references: 15361834
references: Cell Prolif. 1995 Dec;28(12):645-57
references: 8634372
references: Cell Struct Funct. 2000 Jun;25(3):149-59
references: 10984098
references: Nature. 2007 Dec 6;450(7171):908-12
references: 17994007
references: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references: 19474385
references: Mutat Res. 2000 Apr;462(2-3):311-22
references: 10767641
references: Urol Clin North Am. 1999 Aug;26(3):481-92
references: 10494286
references: Gastroenterology. 2005 Nov;129(5):1454-63
references: 16285947
references: J Biol Chem. 2008 Dec 12;283(50):34490-4
references: 18945682
references: Lancet. 2009 Jul 18;374(9685):239-49
references: 19520422
references: Mol Biol Cell. 2007 Mar;18(3):1098-106
references: 17182844
references: Pharmacol Ther. 2007 Sep;115(3):419-34
references: 17658611
references: Br J Cancer. 2003 Jul 7;89(1):120-7
references: 12838312
references: Oncogene. 2005 Nov 10;24(49):7337-45
references: 16007129
references: Genes Cells. 2004 Feb;9(2):131-42
references: 15009091
references: Science. 2007 Sep 21;317(5845):1760-4
references: 17673620
references: Ann N Y Acad Sci. 2003 Dec;1010:300-3
references: 15033738
references: Nature. 2008 Oct 9;455(7214):822-5
references: 18772889